Gujarat Kidney And Super Speciality Limited Stock Analysis

Revenue from operations increased 132.15% YoY to Rs. 1,976.45 lacs in Q3 FY2026 from Rs. 850.64 lacs. / Consolidated revenue reached Rs. 2,324.59 lacs, showing scale beyond standalone operations. / The company remained profitable with reported PAT of Rs. 233.26 lacs and basic/diluted EPS of Rs. 0.41. / Net profit margin is reported at 11.79%, indicating positive bottom-line conversion despite expansion costs. / Financial reporting governance appears sound for the quarter, with an Unmodified Limited Review by Y. M. Shah & Co. and board approval on 14-Feb-2026.

Total expenses rose to Rs. 1,921.11 lacs from Rs. 662.89 lacs YoY, a steep increase that can pressure future margins if growth normalizes. / Cost structure is heavy, including employee cost of Rs. 413.94 lacs, other expenses of Rs. 863.41 lacs, depreciation of Rs. 227 lacs, and finance costs of Rs. 65.24 lacs. / Reported profit figures show internal inconsistency (PBT Rs. 1,168.98 lacs, tax Rs. 83.03 lacs, PAT Rs. 233.26 lacs), creating earnings-quality uncertainty. / No operating cash flow, free cash flow, capex, debt repayment, or liquidity metrics are provided, limiting financial-health assessment. / Risk disclosures indicate concentration in a single primary business segment, increasing exposure to segment-specific demand/regulatory shocks.

Revenue from operations surged 132.15% YoY to Rs. 1976.45 lacs in Q3 FY2026 from Rs. 850.64 lacs in Q3 FY2025, indicating strong demand for specialized kidney care and super specialty medical services / Multi-facility network expansion with consolidated revenue of Rs. 2324.59 lacs covering Gujarat Surgical Hospital, Surya Hospital and ICU, Raj Palmland Hospital, and Harmony Medicare entities, providing geographic diversification / Net profit margin of 11.79% demonstrates reasonable profitability in the competitive healthcare services sector / Employee benefit expenses increased to Rs. 413.94 lacs, reflecting controlled investment in workforce expansion to support revenue growth without disproportionate cost escalation / Unmodified limited review opinion from statutory auditors Y. M. Shah & Co. provides baseline assurance on financial reporting quality for the interim period

Profit after tax data inconsistency showing identical Rs. 233.26 lacs for both Q3 FY2025 and Q3 FY2026 despite 132% revenue growth raises serious concerns about data accuracy and earnings quality / Abnormally low effective tax rate of 7.1% (Rs. 83.03 lacs tax on Rs. 1168.98 lacs PBT) is unexplained and may indicate non-recurring tax benefits or unsustainable tax optimization that could reverse in future periods / Complete absence of balance sheet data, cash flow metrics, debt levels, liquidity ratios, and return on equity/capital metrics prevents assessment of financial leverage, working capital management, and capital efficiency / Total expenses increased 189% to Rs. 1921.11 lacs from Rs. 662.89 lacs YoY, outpacing the 132% revenue growth and suggesting potential margin pressure if cost discipline is not maintained / Single segment concentration in healthcare services with focus on kidney care creates regulatory risk and exposure to changes in government healthcare policies, insurance reimbursement rates, and specialty medical licensing requirements / Depreciation and amortization of Rs. 227 lacs indicates ongoing capital intensity in hospital infrastructure, but absence of capex and free cash flow data prevents evaluation of investment sustainability and cash generation capability